Advertisement


Dejan Juric, MD, on Advanced Breast Cancer: Results From the SOLAR-1 Trial

2018 San Antonio Breast Cancer Symposium

Advertisement

Dejan Juric, MD, of Massachusetts General Hospital, discusses phase III study findings on liquid biopsy–based assessment of PIK3CA mutational status and the combination of the selective PI3K-alpha inhibitor alpelisib plus fulvestrant in the treatment of advanced breast cancer (Abstract GS3-08).



Related Videos

Breast Cancer

Sara A. Hurvitz, MD, on HER2-Positive Breast Cancer: Novel Treatments and Markers

Sara A. Hurvitz, MD, of the University of California, Los Angeles, discusses the natural history and novel combinations for HER2-positive disease as well as predictive and prognost...

Breast Cancer

Andrew D. Seidman, MD, and Miguel Martín, MD, PhD, on Triple-Negative Breast Cancer: Results From the CIBOMA/GEICAM Trial

Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Miguel Martín, MD, PhD, of the Instituto de Investigacion Sanitaria Gregorio Marañón, discuss...

Breast Cancer

Andrew D. Seidman, MD, and Richard G. Gray, MA, MSc, on Long-Term Aromatase Inhibitor Therapy

Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Richard G. Gray, MA, MSc, of the University of Oxford, discuss a meta-analysis of individual ...

Breast Cancer
Issues in Oncology

Kathy S. Albain, MD, on Breast Cancer, Ethnicity, and Clinical Outcomes: Results From the TAILORx Trial

Kathy S. Albain, MD, of Loyola University Stritch School of Medicine, discusses study findings on race, ethnicity, and patient outcomes in hormone receptor–positive, HER2-negative,...

Breast Cancer

Shanu Modi, MD, on Low HER2-Expressing Breast Cancer: Updated Trial Findings

Shanu Modi, MD, of Memorial Sloan Kettering Cancer Center, discusses study findings from a large phase I study on trastuzumab deruxtecan in patients with low HER2-expressing breast...

Advertisement

Advertisement



;
Advertisement